Wow, an interesting experiment and definitely worrisome how these medications can be dangerous for people who don't need them
Meshkat S, Liu Y, Jung H, Tassone VK, Pang H, Janssen-Aguilar R, et al
In a field that demands precision and predictable outcomes, understanding the timeline isn't just about managing expectationsit's about gathering accurate, meaningful data
Regarding our secondary outcomes, SGLT2i users had a lower risk of diabetic nephropathy and a more stable eGFR
Symptoms such as fatigue or constipation may continue for longer, especially with dose escalation
The earlier you see a CVR vein specialist, the more options you have